Tuesday, December 1, 2009

Schizophrenia Home>
News>
Long-acting drug approved for schizophrenia

Font size
- A
- A
- A
Email This

Bookmark

Save

Long-acting drug approved for schizophrenia

(HealthDay News) UPDATED 2009-08-03

The U.S. Food and Drug Administration (FDA) has approved a sustained action form of the antipsychotic Invega for the treatment of schizophrenia. Invega Sustenna is a once-monthly injected medication designed to help prevent symptom relapses in schizophrenia patients who fail to take a more frequent dose of the medicine. FDA officials say the drug should be used with caution by people who have a history of seizure, diabetes, or low white cell count. Read full story >

See all Schizophrenia News

Related: Invega Sustenna

Font size
- A
- A
- A
Email This
Bookmark

Was this helpful? Yes
Save

Note: All clinical content on this site is physician-reviewed, except material generated by our community members.

Non-Profit Affiliates:

Featuring Content From:

By using this service, you accept our Terms of Use. Please read them. The consumer health information on SchizophreniaConnection.com is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2005-2009. The HealthCentral Network, Inc. All rights reserved.

We comply with the HONcode standard for trustworthy health information: verify here.